Seek Returns logo

BAC vs. LLY: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at BAC and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolBACLLY
Company NameBank of America CorporationEli Lilly and Company
CountryUnited StatesUnited States
GICS SectorFinancialsHealth Care
GICS IndustryBanksPharmaceuticals
Market Capitalization358.13 billion USD632.40 billion USD
ExchangeNYSENYSE
Listing DateFebruary 21, 1973June 1, 1972
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of BAC and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

BAC vs. LLY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolBACLLY
5-Day Price Return1.34%3.07%
13-Week Price Return8.00%-6.58%
26-Week Price Return4.36%-19.09%
52-Week Price Return21.88%-23.47%
Month-to-Date Return2.28%-4.68%
Year-to-Date Return10.01%-8.62%
10-Day Avg. Volume32.33M9.65M
3-Month Avg. Volume39.90M4.51M
3-Month Volatility19.69%40.54%
Beta1.360.46

Profitability

Return on Equity (TTM)

BAC

9.46%

Banks Industry

Max
26.37%
Q3
15.92%
Median
12.25%
Q1
8.69%
Min
0.15%

BAC’s Return on Equity of 9.46% is on par with the norm for the Banks industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

BAC vs. LLY: A comparison of their Return on Equity (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

BAC

30.16%

Banks Industry

Max
54.20%
Q3
35.70%
Median
28.97%
Q1
22.53%
Min
6.98%

BAC’s Net Profit Margin of 30.16% is aligned with the median group of its peers in the Banks industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY

25.91%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

BAC vs. LLY: A comparison of their Net Profit Margin (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

BAC

32.74%

Banks Industry

Max
63.35%
Q3
44.59%
Median
37.24%
Q1
28.25%
Min
13.37%

BAC’s Operating Profit Margin of 32.74% is around the midpoint for the Banks industry, indicating that its efficiency in managing core business operations is typical for the sector.

LLY

32.37%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

BAC vs. LLY: A comparison of their Operating Profit Margin (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolBACLLY
Return on Equity (TTM)9.46%88.36%
Return on Assets (TTM)0.84%16.02%
Net Profit Margin (TTM)30.16%25.91%
Operating Profit Margin (TTM)32.74%32.37%
Gross Profit Margin (TTM)--82.64%

Financial Strength

Current Ratio (MRQ)

BAC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

LLY

1.28

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

BAC vs. LLY: A comparison of their Current Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

BAC

2.54

Banks Industry

Max
4.75
Q3
2.62
Median
1.02
Q1
0.39
Min
0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

LLY

2.18

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

BAC vs. LLY: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

BAC

--

Banks Industry

Max
--
Q3
--
Median
--
Q1
--
Min
--

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

BAC vs. LLY: A comparison of their Interest Coverage Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolBACLLY
Current Ratio (MRQ)--1.28
Quick Ratio (MRQ)--0.53
Debt-to-Equity Ratio (MRQ)2.542.18
Interest Coverage Ratio (TTM)--20.36

Growth

Revenue Growth

BAC vs. LLY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

BAC vs. LLY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

BAC

2.66%

Banks Industry

Max
10.27%
Q3
5.83%
Median
3.81%
Q1
2.50%
Min
0.00%

BAC’s Dividend Yield of 2.66% is consistent with its peers in the Banks industry, providing a dividend return that is standard for its sector.

LLY

0.77%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

BAC vs. LLY: A comparison of their Dividend Yield (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

BAC

33.91%

Banks Industry

Max
147.07%
Q3
80.55%
Median
54.40%
Q1
35.71%
Min
0.00%

BAC’s Dividend Payout Ratio of 33.91% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

LLY

36.46%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

BAC vs. LLY: A comparison of their Dividend Payout Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolBACLLY
Dividend Yield (TTM)2.66%0.77%
Dividend Payout Ratio (TTM)33.91%36.46%

Valuation

Price-to-Earnings Ratio (TTM)

BAC

12.73

Banks Industry

Max
20.05
Q3
12.65
Median
10.21
Q1
7.54
Min
2.74

A P/E Ratio of 12.73 places BAC in the upper quartile for the Banks industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

LLY

47.48

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

BAC vs. LLY: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

BAC

2.33

Banks Industry

Max
5.06
Q3
2.98
Median
2.24
Q1
1.59
Min
0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

LLY

12.30

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

BAC vs. LLY: A comparison of their Price-to-Sales Ratio (TTM) against their respective Banks and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

BAC

1.17

Banks Industry

Max
2.18
Q3
1.36
Median
1.09
Q1
0.81
Min
0.20

BAC’s P/B Ratio of 1.17 is within the conventional range for the Banks industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

BAC vs. LLY: A comparison of their Price-to-Book Ratio (MRQ) against their respective Banks and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolBACLLY
Price-to-Earnings Ratio (TTM)12.7347.48
Price-to-Sales Ratio (TTM)2.3312.30
Price-to-Book Ratio (MRQ)1.1740.43
Price-to-Free Cash Flow Ratio (TTM)8.12326.03